A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

Exclusion Criteria

• •previous chemotherapy for metastatic or locally recurrent breast cancer;
• •previous radiotherapy for metastatic breast cancer (except for metastatic bone pain relief);
• •other primary tumor within last 5 years, with the exception of basal or squamous skin cancer, or in situ cancer of the cervix;
• •clinically significant cardiovascular disease;
• •chronic daily treatment with aspirin (\>325mg/day) or clopidogrel (\>75mg/day).